MONTREAL — A simple blood test may soon be able to predict how long older adults have to live, according to a new study from researchers at Duke University.
The test focuses on RNA interacting with Piwi (piARN), a class of genetic molecules that play a role in development, regeneration, and the immune response. This research offers a potential new way to assess the health and prognosis of seniors, a growing segment of the population.
In trials, the experimental analysis accurately predicted which of the tested seniors would still be alive two years later, with a precision rate of 86%. Researchers believe this breakthrough could eventually lead to more targeted and effective healthcare for older individuals.
“I reckon the next step is to understand how these molecules work in relation to health, to identify potential therapeutic targets,” said Professor Francis Migneault, from the Department of Microbiology, Infectiology and Immunology at the University of Montreal. “For people at risk of dying, how can we prevent that?”
The piARN analysis outperformed traditional clinical measurements – including age, cholesterol levels, and physical activity – as well as over 180 other health metrics in predicting short-term survival, according to a statement released by Duke Health.
The team measured piARN levels in blood samples taken from adults aged 71 and older. Participants who lived longer consistently showed lower levels of specific piARNs, mirroring a phenomenon previously observed in simpler organisms like worms.
Statistical modeling revealed that a group of just six piARNs could predict two-year survival with 86% accuracy. The team confirmed these findings with a second, independent group of seniors.
While lifestyle factors remain vital for long-term survival, the study authors suggest piARNs provide valuable insights into the underlying biology of aging.
Although, experts caution against drawing conclusions too quickly. “One study is never the end of the story,” said Dr. Marie-Josée Hébert, a nephrologist-researcher at the Montreal University Health Centre. “We require to be able to reproduce the same results in other databases with different patients. If the study is repeated, do we find the same thing?”
The exact role of piARNs in the body remains unclear, but the study authors believe elevated levels of these molecules in the blood could indicate a health problem and warrant further investigation.
“We are really far from understanding the mechanism,” Dr. Hébert admitted. “We don’t yet recognize if these molecules cause aging, or if they are a consequence of underlying degradation. We are really at the beginning of understanding how these molecules work.”
A simple blood test could one day facilitate identify survival risks earlier and guide therapeutic strategies to promote healthy aging, researchers say.
The study likewise raises important ethical considerations, Professor Migneault noted. “It brings a particular issue for the psychological burden on patients, namely, do they want to know if they are at risk of dying in the next two years?” he said.
Dr. Hébert believes a “responsible” use of this information would focus on prevention. “Once we know, what can we change to prevent, and to inform, but not to condemn?” she asked. “How can we have a positive and preventative discussion with patients? Because it would be terrible to have a test and tell a patient, ‘you have reached the end of your life expectancy, you only have two years left, and we do nothing.’ There isn’t a doctor in the world who would want to approach it that way.”
The study’s findings were published in the medical journal Aging Cell.
